Craif Inc. announced that Iwata Chizaki Construction Co., Ltd. has adopted the 'Misignal Scan' urine cancer risk test as part of its employee benefits program.

Purpose of Implementation Iwata Chizaki Construction believes that strengthening health promotion efforts is essential to create an environment where each employee can maintain their health and work enthusiastically for the future. Given this background, the company has introduced the 'Misignal Scan' as part of its health-related benefits starting this fiscal year. The company evaluated the product for its ease of use—requiring only a urine sample—and its ability to detect risks for up to 10 types of cancer, even at Stage 1. Through this initiative, the company aims to raise employees' health awareness, facilitate early disease detection, and further advance its 'Health and Productivity Management.'

About 'Misignal Scan' Misignal Scan is a cancer risk test that extracts and analyzes microRNA from urine to determine the risk of up to 10 types of cancer from Stage 1 with high precision. As a urine test, it imposes no physical burden and can be performed from home via mail, minimizing effort. It has been adopted by over 2,000 medical institutions nationwide, and results, such as early detection of lung cancer, have been reported in Hokkaido.

[10 Cancer Types Detected] Lung, Colorectal, Pancreatic, Gastric, Esophageal, Kidney, Bladder, Prostate (men only), Breast (women only), Ovarian (women only).

* The Misignal series is not a medical device. It is not a substitute for a medical diagnosis, and a low-risk result does not guarantee the absence of cancer.

About Craif Craif Inc. is a Bio-AI startup focused on early cancer detection. By combining its proprietary analytical technology platform, 'NANO IP®,' with AI, the company is developing innovative tests to enable ultra-early cancer detection. Its vision is to realize a society where people can live out their full natural lifespans.

FACT BOX

  • Source: PR TIMES
  • Category: News